Asgard Therapeutics is a private biotech company pioneering in vivo direct reprogramming for cancer immunotherapy. Formed as a spin-off from Lund University, the company is pioneering a gene therapy approach based on its proprietary reprogramming technology, designed to set in motion immune responses based on the biological properties of professional antigen-presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund, and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized for each unique patient.
Cristiana Pires holds a degree in Pharmaceutical Sciences and PhD in Cell Reprogramming. She founded Asgard Therapeutics in 2018 together with the other two inventors of TrojanDC, Associate Professor Filipe Pereira and Fábio Rosa, MSc. Now, by combining her pharmaceutical and scientific background with entrepreneurship experience, Cristiana is motivated to bring TrojanDC to the patients.
Did you know?
Asgard’s scientific founders are from Portugal and decided to honor the Swedish affiliation by choosing a name inspired by the Norse Mythology.